Clinical studies have not yet determined a common mechanism of action for antidepressant
drugs, which have primary sites of action on a variety of different neurotransmitter systems …

Depression is a leading cause of disability. Current pharmacological treatment of
depression is insufficient, and development of improved treatments especially for treatment …

Several hypotheses regarding the physiopathology of major depression exist. Attention has
been focused on cerebral monoaminergic systems, the dysfunction of which is thought to …

The mesolimbic dopaminergic system functions as a major reward pathway in the CNS and
is an appropriate target for antidepressant drugs. This review describes the principal …

In the last decade, many new antidepressants have been developed that display a more
rapid onset to clinical effects than classical antidepressants. However, the mechanism that …

Multiple sources of evidence support a role for diminished dopaminergic neurotrans-mission
in major depression. The physiological alterations underlying reduced dopa-mine (DA) …

Chronic treatment with antidepressant drugs produces a variety of changes in dopaminergic
neurotransmission. most notably a sensitization of behavioural responses to agonists acting …

The monoamine hypothesis of depression suggests that depressive symptoms can be
moderated by enhancing monoamine neurotransmission. Targeted neurotransmitters …

Most antidepressants in use today are descendants of the monoamine oxidase inhibitor
iproniazid and the tricyclic agent imipramine. These agents were both originally developed …

Converging lines of evidence suggest a role for the mesolimbic dopamine system in the
response to somatic antidepressant therapies. Here, we review evidence suggesting that …